Candel Therapeutics, Inc. (CADL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
117 Kendrick Street
Needham, MA 02494
United States of America (the)
Phone
617 916 5445
Website
Sector
Healthcare
Industry
Biotechnology
Employees
38
First IPO Date
July 27, 2021
| Name | Title | Pay | Year Born |
| Paul-Peter Tak FOCIS | President, Chief Executive Officer & Director | 1.03M | 1961 |
| Charles Schoch | Senior VP, CFO, Treasurer & Secretary | 412,032 | 1985 |
| Francesca Barone | Chief Scientific Officer | 497,312 | 1978 |
| Seshu Tyagarajan | Chief Technical & Development Officer | 613,231 | 1968 |
| William Nichols Garrett | Chief Medical Officer | 0 | 1969 |
| Ileen Winick | Chief People Officer | 0 | N/A |
| Susan Stewart | Chief Regulatory Officer | 0 | 1961 |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.